Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Dermatologic 1

Conditions

Uterine Cervical Dysplasia 2Squamous Intraepithelial Lesions 2Skin Neoplasms 1Sarcoma, Kaposi 1Lymphoproliferative Disorders 1HIV Infections 1Acquired Immunodeficiency Syndrome 1

Interventions

dacetuzumab 7blinatumomab 6Rituximab 5ibrutinib 3Cyclophosphamide 3venetoclax 2tetulomab tetraxetan lu-177 2ponatinib 2fludarabine 2ferric carboxymaltose 2cobomarsen 2Vorinostat 2Valganciclovir 2Lutetium 2Lenalidomide 2Ifosfamide 2Ganciclovir 2Everolimus 2Dexamethasone 2Bortezomib 2ruxolitinib 1pomalidomide 1pegaspargase 1ficlatuzumab 1epratuzumab 1enzalutamide 1durvalumab 1denileukin diftitox 1cirmtuzumab 1asparaginase erwinia chrysanthemi recombinant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoproliferative Disorders × 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone × Clear all
NCT00002153 2005-06-24

Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders

NIH AIDS Clinical Trials Information Service

Phase 1 Completed
25 enrolled
DermatologicLymphoidSarcoma

Acquired Immunodeficiency Syndrome, Lymphoproliferative Disorders, Sarcoma, Kaposi, Skin Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡